| 期刊論文| 1. | 虞希禹、劉致和、陳益祥、王水深、朱樹勳、林芳郁(20050400)。Relationship of International Normalized Ratio to Bleeding and Thromboembolism Rates in Taiwanese Patients Receiving Vitamin K Antagonist after Mechanical Valve Replacement。臺灣醫學會雜誌，104(4)，236-243。 延伸查詢 | | 2. | Guyatt, G. H.、Akl, E. A.、Crowther, M.、Gutterman, D. D.、Schuiinemann, H. J.(2012)。Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines。Chest，141，7-47。  | | 3. | Singer, D. E.、Chang, Y.、Fang, M. C.、Borowsky, L. H.、Pomernacki, N. K.、Udaltsova, N.(2009)。Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study。Circ Cardiovasc Qual Outcomes，2，297-304。 | | 4. | Brvar, M.、Fokter, N.、Bunc, M.、Mozina, M.(2009)。The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty。BMC Clin Pharmacol，9，1-8。 | | 5. | Dang, M. T.、Hambleton, J.、Kayser, S. R.(2005)。The influence of ethnicity on warfarin dosage requirement。Ann Pharmacother，39，1008-1012。 | | 6. | Cheung, C. M.、Tsoi, T. H.、Huang, C. Y.(2005)。The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation。Cerebrovasc Dis，20，114-119。 | | 7. | Yasaka, M.、Minematsu, K.、Yamaguchi, T.(2001)。Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation。Intern Med，40，1183-1188。 | | 8. | Yamaguchi, T.(2000)。Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation--Embolism Secondary Prevention Cooperati。Stroke，31，817-821。 | | 9. | Haibo, Z.、Jinzhong, L.、Yan, L.、Xu, M.(2012)。Low-intensity international normalized ratio (INR) oral anticoagulant therapy in Chinese patients with mechanical heart valve prostheses。Cell Biochem Biophys，62，147-151。 | | 10. | Chen, K. P.、Huang, C. X.、Huang, D. J.、Cao, K. J.、Ma, C. S.、Wang, F. Z.(2012)。Anticoagulation therapy in Chinese patients with non-valvular atrial fibrillation: a prospective, multi-center, randomized, controlled study。Chin Med J (Engl)，125，4355-4360。 | | 11. | Liu, Y.、Yu, X. Y.、Zhong, S. L.、Yang, M.、Tan, H. H.、Fei, H. W.(2010)。Clinical application of anticoagulation treatment with warfarin after prosthetic heart valve replacement: a single center-based survey。Nan Fang Yi Ke Da Xue Xue Bao，30，2242-2245。 | | 12. | Yang, P.、Wu, Q. H.、Luo, X. Y.、Kou, L.、Chen, Z.、Zhang, Y. Y.(2009)。The study of Chinese optimal anticoagulant range of warfarin for venous thromboembolism。Zhonghua Yi Xue Za Zhi，89，1762-1765。 | | 13. | You, J. H.、Chan, F. W.、Wong, R. S.、Cheng, G.(2005)。Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?。Br J Clin Pharmacol，59，582-587。 | | 14. | Dong, L.、Shi, Y. K.、Tian, Z. P.、Ma, J. Y.、Wang, X.、Yi, J.(2003)。Low intensity anticoagulation therapy after mechanical heart valve replacement。Zhonghua Wai Ke Za Zhi，41，250-252。 | | 15. | Chenhsu, R. Y.、Chiang, S. C.、Chou, M. H.、Lin, M. F.(2000)。Long-term treatment with warfarin in Chinese population。Ann Pharmacother，34，1395-1401。 | | 16. | Zhuang, W.、Zhou, X. M.、Hu, J. G.、Li, J. M.、Yu, J. F.、Jiang, L.(2004)。Anticoagulation in Chinese patients with carbomedics mechanical prosthetic heart valves。Zhong Nan Da Xue Xue Bao Yi Xue Ban，29，460-462。 | | 17. | Naganuma, M.、Shiga, T.、Sato, K.、Murasaki, K.、Hashiguchi, M.、Mochizuki, M.(2012)。Clinical outcome in Japanese elderly patients with non- valvular atrial fibrillation taking warfarin: a single-center observational study。Thromb Res，130，21-26。 | | 18. | Nakamura, A.、Ago, T.、Kamouchi, M.、Hata, J.、Matsuo, R.、Kuroda, J.(2013)。Intensity of anticoagulation and clinical outcomes in acute cardioembolic stroke: the Fukuoka Stroke Registry。Stroke，44，3239-3242。 | | 19. | Yoon, I. K.、Lee, K. E.、Lee, J. K.、Chang, B. C.、Gwak, H. S.(2013)。Adequate intensity of warfarin therapy for Korean patients with mechanical cardiac valves。J Heart Valve Dis，22，102-109。 | | 20. | Holbrook, A.、Schulman, S.、Witt, D. M.、Vandvik, P. O.、Fish, J.、Kovacs, M. J.(2012)。Evidence- based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines。Chest，141，152-184。 | | 21. | Anderson, J. L.、Halperin, J. L.、Albert, N. M.、Bozkurt, B.、Brindis, R. G.、Curtis, L. H.(2013)。Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines。J Am Coll Cardiol，61，1935-1944。 | | 22. | Camm, A. J.、Lip, G. Y.、De Caterina, R.、Savelieva, I.(2012)。2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association。Eur Heart J.，33，2719-2747。 | | 23. | Takarada, K.、Sato, M.、Goto, M.、Saito, A.、Ikeda, Y.、Fujita, S.(2014)。Long-term PT-INR levels and the clinical events in the patients with non- valvular atrial fibrillation: a special reference to low-intensity warfarin therapy。J Cardiol，64，127-132。 | | 24. | Hirsh, J.、Fuster, V.、Ansell, J.、Halperin, J. L.(2003)。American Heart Association, American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy。Circulation，107，1692-1711。 | | 25. | Schelleman, H.、Limdi, N. A.、Kimmel, S. E.(2008)。Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics。Pharmacogenomics，9，1331-1346。 | | 26. | Kearon, C.、Kahn, S. R.、Agnelli, G.、Goldhaber, S.、Raskob, G. E.、Comerota, A. J.(2008)。Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition。Chest，133，454-545。 | | 27. | Heneghan, C.、Tyndel, S.、Bankhead, C.、Wan, Y.、Keeling, D.、Perera, R.(2010)。Optimal loading dose for the initiation of warfarin: a systematic review。BMC Cardiovasc Disord，10，18。 | | 28. | Kimmel, S. E.、French, B.、Kasner, S. E.、Johnson, J. A.、Anderson, J. L.、Gage, B. F.(2013)。Apharmacogenetic versus a clinical algorithm for warfarin dosing。N Engl J Med，369，2283-2293。 | | 29. | You, J. J.、Singer, D. E.、Howard, P. A.、Lane, D. A.、Eckman, M. H.、Fang, M. C.(2012)。Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines。Chest，141，531-575。 | | 30. | American College of Cardiology Foundation、American Heart Association、European Society of Cardiology、Heart Rhythm Society、Wann, L. S.、Curtis, A. B.(2013)。Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/ AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines。Circulation，127，1916-1926。 | | 31. | Bonow, R. O.、Carabello, B. A.、Chatterjee, K.、de Leon, A. C. Jr.、Faxon, D. P.、Freed, M. D.(2008)。2008 Focused update incorporated into the ACC/ AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing commit。Circulation，118，523-661。 | | 32. | Vahanian, A.、Alfieri, O.、Andreotti, F.、Antunes, M. J.、Baron-Esquivias, G.、Baumgartner, H.(2012)。Guidelines on the management of valvular heart disease (version 2012)。Eur Heart J.，33，2451-2496。 | | 33. | Whitlock, R. P.、Sun, J. C.、Fremes, S. E.、Rubens, F. D.、Teoh, K. H.、American College of Chest Physicians(2012)。Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines。Chest，141，576-600。 | | 34. | Kearon, C.、Akl, E. A.、Comerota, A. J.、Prandoni, P.、Bounameaux, H.、Goldhaber, S. Z.(2012)。Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines。Chest，141，419-494。 | 圖書論文| 1. | Wittkowsky, A. K.(2009)。Initiation and Maintenance Dosing of Warfarin and Monitoring the INR。Managing Oral Anticoagulation Therapy。St. Louis：Wolters Kluwer Health。 | |
| |